| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Medical and professional news |
| Population | Women |
| Source | Elite NP (Elite Learning) |
| URL | elitenp.com/?p=13498 (opens in a new tab) |
Specific Claim Evaluated
Testosterone directly supports bone density, muscle mass, cognitive function and sexual desire, and testosterone therapy can address low energy, reduced libido and mood changes in perimenopause.
Primary Research Supporting or Contradicting the Claim
The consensus statement finds evidence only for postmenopausal hypoactive sexual desire disorder and insufficient evidence for bone, muscle, cognition, mood or use in premenopausal women (Davis et al., 2019). A 2026 meta-analysis found insufficient evidence for a cognitive effect (Faulkner et al., 2026).
Corrected Evidence-Based Interpretation
Testosterone has no established role in perimenopause and no evidence of benefit for energy, mood, bone or cognition. Its only evidence-based use is postmenopausal hypoactive sexual desire disorder.
Rationale for Grade
The article is directed at nurse practitioners and recommends testosterone for perimenopausal symptoms without citation, contrary to consensus guidance. This is a substantive departure from the evidence in content intended for prescribers.
References
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD." - Faulkner A, Desai R, Keay N, Ellahi SA, Spector A. Testosterone therapy for cognition in menopause: a systematic review and meta-analysis. Reprod Fertil. 2026;7(4). PMID
Supporting excerpt: "insufficient to establish an effect rather than as evidence of no effect"